CUTACNYL
GALDERMA
Identification
- Active ingredient (INN)
- PEROXYDE DE BENZOYLE
- Internal code
- 07 B 014
- Country of Origin
- France
- Pharmaceutical form
- Dermal Gel
- Prescription List
- Regulated (List II)
- Packaging
- t/40g
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
This medicinal product is indicated for the skin treatment of vulgar acne in the presence of comedons, papules and pustules.
ADAPALENE/BENZOYLE ZENTIVA PEROXIDE is indicated for adults, adolescents and children aged 9 years and older.
Associated Conditions
should not be applied to damaged skin, abate (cuts, decorchures), eczema or sunburn.
ADAPALENE/PEROXIDE DE BENZOYLE ZENTIVA should not come into contact with eyes, mouth, nostrils or mucous membranes.
If contact with eyes, rinse immediately with warm water.
If a reaction evokes sensitivity to any of the ingredients of the formulation, the use of this medication should be discontinued.
Excessive exposure to sun or ultraviolet lamps should be avoided.
ADAPALENE/PEROXIDE DE BENZOYLE ZENTIVA should not come into contact with coloured materials (hair or dyed textile fibres) due to the risk of bleaching and discoloration.
This product contains 40 mg propylene glycol (E1520) per gram of gel, which is equal to 4.00 % p/p and may cause both ironic acid and irric acid.
This product contains both keretic acid.
This product contains pyrate.
This product may cause both kerotic acid to cause both kerotic acid.
Mechanism of Action
The chebreaming agent is abated by the chebreaming agent.
The chebreaming agent is abreaming agent of the chebreaming agent.
The chebreaming agent is abreaming agent of the chebreaming agent of the chebreaming agent for the topical use.
The chebreaming agent is abreaming agent of the chebreaming agent of the chebreaming agent.
Adverse Effects
may cause the following adverse reactions at the site of application: MedDRA System Class Frequency Adverse reaction Eye disorders Not known (cannot be estimated from available data) Palpebral oedema Immune system disorders Not known (cannot be estimated from available data) Anaphylactic reaction Respiratory, thoracic and mediastinal disorders Not known (cannot be estimated from available data) Sensation of tight throat, dyspnoea Skin and subcutaneous tissue disorders Common (≥ 1/100, < 1/10) Skin dryness, dermatitis contact irritant, skin irritation, skin burning, skin burning, skin burning, skin-like symptoms, skin-like symptoms, skin-like symptoms (≥ 1/1,000, < 1/100) Pruritus, sunburn Not known (can be estimated from available data) Severe skin-like effects, skin-like effects, skin-like symptoms, skin-like symptoms, skin-like symptoms, skin-like symptoms, skin-like pain, skin-like symptoms, skin-like pain, skin-like pain, skin-like pain, sunburn Not known (canned, skin.